CollPlant Biotechnologies Ltd. cash flow to debt ratio of -330.96% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

CollPlant Biotechnologies Ltd.'s free cash flow has increased 35.19% from $-14.58M last year to $-9.45M, signaling increasing performance

CollPlant Biotechnologies Ltd.'s debt to equity ratio is 0.90, which means that the company's assets are unhealthy financed, signaling financial risk.

CollPlant Biotechnologies Ltd.'s debt has increased relative to shareholder equity from 0.23 last year to 0.90 today, signaling weakened financials

CollPlant Biotechnologies Ltd. has a net cash position, so leverage is healthy.

CollPlant Biotechnologies Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

CollPlant Biotechnologies Ltd.'s profit margin was -3.23K% last year and is -3.93K% this year, signaling decreasing performance

CollPlant Biotechnologies Ltd.'s short-term assets of $6.75M exceed its short-term liabilities of $2.67M

CollPlant Biotechnologies Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

CollPlant Biotechnologies Ltd.'s return on equity of -215.58%, is lower than 15.00%, indicating bad performance

CollPlant Biotechnologies Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

CollPlant Biotechnologies Ltd. had positive net income in only 1 out of 5 years, indicating unstable earnings

CollPlant Biotechnologies Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

CollPlant Biotechnologies Ltd. has negative free cash flow, indicating cash burn

CollPlant Biotechnologies Ltd.'s yearly earnings has increased 30.83% since last year from $-16.61M to $-11.49M, signaling increasing performance

CollPlant Biotechnologies Ltd.'s yearly revenue has increased 360.39% since last year from $515.00K to $2.37M, signaling increasing performance

ROIC -221.32% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

CollPlant Biotechnologies Ltd.'s 3-year revenue CAGR of 99.41% is positive, indicating growing revenue over the past 3 years

CollPlant Biotechnologies Ltd. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

CollPlant Biotechnologies Ltd. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

CollPlant Biotechnologies Ltd. has insufficient data to evaluate this check.

CollPlant Biotechnologies Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CollPlant Biotechnologies Ltd. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

CollPlant Biotechnologies Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

CollPlant Biotechnologies Ltd. has insufficient data to evaluate this check.

CollPlant Biotechnologies Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

CollPlant Biotechnologies Ltd. has a price-to-book ratio of 1.80x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

CollPlant Biotechnologies Ltd. has a price-to-sales ratio of 16.65x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue